Aptus Pharma IPO
Live Updates, GMP, Subscription Data, and Financial Details
IPO Overview
Listed
Dates
Sep 23 to Sep 25 2025
Price Band
₹65 - 70
Current GMP
₹4(5.71%)
Subscription
22.27 times
IPO Details
| IPO Date | September 23, 2025 to September 25, 2025 |
| Listing Date | September 30, 2025 |
| Face Value | ₹10 per share |
| Issue Price Band | ₹65 to ₹70 per share |
| Issue Price Final | ₹70 per share |
| Lot Size | 2,000 Shares |
| Sale Type | Fresh Capital |
| Total Issue Size | 18,60,000 shares (aggregating up to ₹13.02 Cr) |
| Reserved for Market Maker | 94,000 shares (aggregating up to ₹0.6580 Cr)Market-Hub Stock Broking Pvt.Ltd. |
| Net Offered to Public | 17,66,000 shares (aggregating up to ₹12.36 Cr) |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE SME |
| Share Holding Pre Issue | 50,00,000 shares |
| Share Holding Post Issue | 68,60,000 shares |
IPO Date
September 23, 2025 to September 25, 2025
Listing Date
September 30, 2025
Face Value
₹10 per share
Issue Price Band
₹65 to ₹70 per share
Issue Price Final
₹70 per share
Lot Size
2,000 Shares
Sale Type
Fresh Capital
Total Issue Size
18,60,000 shares (aggregating up to ₹13.02 Cr)
Reserved for Market Maker
94,000 shares (aggregating up to ₹0.6580 Cr)Market-Hub Stock Broking Pvt.Ltd.
Net Offered to Public
17,66,000 shares (aggregating up to ₹12.36 Cr)
Issue Type
Bookbuilding IPO
Listing At
BSE SME
Share Holding Pre Issue
50,00,000 shares
Share Holding Post Issue
68,60,000 shares
IPO Subscription Details
| Anchor Investors | 1 |
| Market Maker | 1 |
| QIB (Ex Anchor) | 1.24 |
| Non-Institutional Buyers*** | 28.75 |
| bNII (bids above ₹10L) | 30.64 |
| sNII (bids below ₹10L) | 24.93 |
| Individual Investors (IND category bidding for 2 Lots) | 31.43 |
| Total ** | 22.27 |
Anchor Investors
1
Market Maker
1
QIB (Ex Anchor)
1.24
Non-Institutional Buyers***
28.75
bNII (bids above ₹10L)
30.64
sNII (bids below ₹10L)
24.93
Individual Investors (IND category bidding for 2 Lots)
31.43
Total **
22.27
Day Wise Sub
| Day | QIB (Ex Anchor) | NII* | NII (> ₹10L) | NII (< ₹10L) | Individual Investors | Total |
|---|---|---|---|---|---|---|
| Day 1 Sep 23, 2025 | 0.00 | 4.78 | 5.84 | 2.64 | 1.77 | 1.92 |
| Day 2 Sep 24, 2025 | 0.81 | 6.16 | 7.15 | 4.16 | 5.46 | 4.29 |
| Day 3 Sep 25, 2025 | 1.24 | 28.75 | 30.64 | 24.93 | 31.43 | 22.27 |
DayDay 1
Sep 23, 2025
QIB (Ex Anchor)0.00
NII*4.78
NII (> ₹10L)5.84
NII (< ₹10L)2.64
Individual Investors1.77
Total1.92
DayDay 2
Sep 24, 2025
QIB (Ex Anchor)0.81
NII*6.16
NII (> ₹10L)7.15
NII (< ₹10L)4.16
Individual Investors5.46
Total4.29
DayDay 3
Sep 25, 2025
QIB (Ex Anchor)1.24
NII*28.75
NII (> ₹10L)30.64
NII (< ₹10L)24.93
Individual Investors31.43
Total22.27
Day Wise GMP
| Date | Price | GMP | Estimate List Price |
|---|---|---|---|
| 30-09-2025 | 70.00 | 4(5.71%) | 74 |
| 29-09-2025 | 70.00 | 4(5.71%) | 74 |
| 28-09-2025 | 70.00 | 4(5.71%) | 74 |
| 27-09-2025 | 70.00 | 4(5.71%) | 74 |
| 26-09-2025 | 70.00 | 4(5.71%) | 74 |
| 25-09-2025 | 70.00 | 4(5.71%) | 74 |
| 24-09-2025 | 70.00 | 8(11.43%) | 78 |
| 23-09-2025 | 70.00 | 7(10.00%) | 77 |
| 22-09-2025 | 70.00 | 7(10.00%) | 77 |
| 21-09-2025 | 70.00 | 7(10.00%) | 77 |
| 20-09-2025 | 70.00 | 7(10.00%) | 77 |
| 19-09-2025 | 70.00 | 7(10.00%) | 77 |
| 18-09-2025 | 70.00 | 0(0.00%) | 70 |
| 17-09-2025 | 70.00 | 0(0.00%) | 70 |
| 16-09-2025 | 70.00 | 0(%) | (%) |
Date30-09-2025
Price70.00
GMP4(5.71%)
Estimate List Price74
Date29-09-2025
Price70.00
GMP4(5.71%)
Estimate List Price74
Date28-09-2025
Price70.00
GMP4(5.71%)
Estimate List Price74
Date27-09-2025
Price70.00
GMP4(5.71%)
Estimate List Price74
Date26-09-2025
Price70.00
GMP4(5.71%)
Estimate List Price74
Date25-09-2025
Price70.00
GMP4(5.71%)
Estimate List Price74
Date24-09-2025
Price70.00
GMP8(11.43%)
Estimate List Price78
Date23-09-2025
Price70.00
GMP7(10.00%)
Estimate List Price77
Date22-09-2025
Price70.00
GMP7(10.00%)
Estimate List Price77
Date21-09-2025
Price70.00
GMP7(10.00%)
Estimate List Price77
Date20-09-2025
Price70.00
GMP7(10.00%)
Estimate List Price77
Date19-09-2025
Price70.00
GMP7(10.00%)
Estimate List Price77
Date18-09-2025
Price70.00
GMP0(0.00%)
Estimate List Price70
Date17-09-2025
Price70.00
GMP0(0.00%)
Estimate List Price70
Date16-09-2025
Price70.00
GMP0(%)
Estimate List Price(%)
IPO Important Dates
| IPO Open Date | Tue, Sep 23, 2025 |
| IPO Close Date | Thu, Sep 25, 2025 |
| Tentative Allotment | Fri, Sep 26, 2025 |
| Initiation of Refunds | Mon, Sep 29, 2025 |
| Credit of Shares to Demat | Mon, Sep 29, 2025 |
| Tentative Listing Date | Tue, Sep 30, 2025 |
| Cut-off time for UPI mandate confirmation | 5 PM on Thu, Sep 25, 2025 |
IPO Open Date
Tue, Sep 23, 2025
IPO Close Date
Thu, Sep 25, 2025
Tentative Allotment
Fri, Sep 26, 2025
Initiation of Refunds
Mon, Sep 29, 2025
Credit of Shares to Demat
Mon, Sep 29, 2025
Tentative Listing Date
Tue, Sep 30, 2025
Cut-off time for UPI mandate confirmation
5 PM on Thu, Sep 25, 2025
IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Individual investors (Retail) (Min) | 2 | 4,000 | ₹2,80,000 |
| Individual investors (Retail) (Max) | 2 | 4,000 | ₹2,80,000 |
| S-HNI (Min) | 3 | 6,000 | ₹4,20,000 |
| S-HNI (Max) | 7 | 14,000 | ₹9,80,000 |
| B-HNI (Min) | 8 | 16,000 | ₹11,20,000 |
ApplicationIndividual investors (Retail) (Min)
Lots2
Shares4,000
Amount₹2,80,000
ApplicationIndividual investors (Retail) (Max)
Lots2
Shares4,000
Amount₹2,80,000
ApplicationS-HNI (Min)
Lots3
Shares6,000
Amount₹4,20,000
ApplicationS-HNI (Max)
Lots7
Shares14,000
Amount₹9,80,000
ApplicationB-HNI (Min)
Lots8
Shares16,000
Amount₹11,20,000
Financial Information
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
| Assets | 21.92 | 10.03 | 6.22 |
| Total Income | 24.64 | 17.88 | 13.90 |
| Profit After Tax | 3.10 | 0.80 | 0.19 |
| EBITDA | 4.76 | 1.49 | 0.57 |
| Net Worth | 6.97 | 1.77 | 0.97 |
| Reserves and Surplus | 1.97 | 1.47 | 0.67 |
| Total Borrowing | 10.36 | 5.31 | 2.21 |
Period EndedPeriod Ended
31 Mar 202531 Mar 2025
31 Mar 202431 Mar 2024
31 Mar 202331 Mar 2023
Period EndedAssets
31 Mar 202521.92
31 Mar 202410.03
31 Mar 20236.22
Period EndedTotal Income
31 Mar 202524.64
31 Mar 202417.88
31 Mar 202313.90
Period EndedProfit After Tax
31 Mar 20253.10
31 Mar 20240.80
31 Mar 20230.19
Period EndedEBITDA
31 Mar 20254.76
31 Mar 20241.49
31 Mar 20230.57
Period EndedNet Worth
31 Mar 20256.97
31 Mar 20241.77
31 Mar 20230.97
Period EndedReserves and Surplus
31 Mar 20251.97
31 Mar 20241.47
31 Mar 20230.67
Period EndedTotal Borrowing
31 Mar 202510.36
31 Mar 20245.31
31 Mar 20232.21
Peers Comparison
| Company Name | EPS (Basic) | EPS (Diluted) | NAV (per share) (Rs) | P/E (x) | RoNW (%) | P/BV Ratio |
|---|---|---|---|---|---|---|
| Aptus Pharma Limited | 5.32 | 5.32 | 13.93 | 44.50 | ||
| Zota Health Care Limited | 3.16 | 3.16 | 110.83 | 382.12 | 2.72 | 10.97 |
| Sunrest Lifescience Limited | 4.66 | 4.66 | 37.72 | 10.56 | 12.36 | 1.32 |
| Lincoln Pharmaceuticals Limited | 41.11 | 41.11 | 335.34 | 13.53 | 12.26 | 1.66 |
Company NameAptus Pharma Limited
EPS (Basic)5.32
EPS (Diluted)5.32
NAV (per share) (Rs)13.93
P/E (x)
RoNW (%)44.50
P/BV Ratio
Company NameZota Health Care Limited
EPS (Basic)3.16
EPS (Diluted)3.16
NAV (per share) (Rs)110.83
P/E (x)382.12
RoNW (%)2.72
P/BV Ratio10.97
Company NameSunrest Lifescience Limited
EPS (Basic)4.66
EPS (Diluted)4.66
NAV (per share) (Rs)37.72
P/E (x)10.56
RoNW (%)12.36
P/BV Ratio1.32
Company NameLincoln Pharmaceuticals Limited
EPS (Basic)41.11
EPS (Diluted)41.11
NAV (per share) (Rs)335.34
P/E (x)13.53
RoNW (%)12.26
P/BV Ratio1.66
IPO Reservation
| Market Maker Shares Offered | 94,000 (5.05%) |
| QIB Shares Offered | 8,80,000 (47.31%) |
| − Anchor Investor Shares Offered | 5,28,000 (28.39%) |
| − QIB (Ex. Anchor) Shares Offered | 3,52,000 (18.92%) |
| NII (HNI) Shares Offered | 2,66,000 (14.30%) |
| − bNII > ₹10L | 1,78,000 (9.57%) |
| − sNII < ₹10L | 88,000 (4.73%) |
| Retail Shares Offered | 6,20,000 (33.33%) |
| Total Shares Offered | 18,60,000 (100.00%) |
Market Maker Shares Offered
94,000 (5.05%)
QIB Shares Offered
8,80,000 (47.31%)
− Anchor Investor Shares Offered
5,28,000 (28.39%)
− QIB (Ex. Anchor) Shares Offered
3,52,000 (18.92%)
NII (HNI) Shares Offered
2,66,000 (14.30%)
− bNII > ₹10L
1,78,000 (9.57%)
− sNII < ₹10L
88,000 (4.73%)
Retail Shares Offered
6,20,000 (33.33%)
Total Shares Offered
18,60,000 (100.00%)
Information about company
Incorporated in 2010, Aptus Pharma Ltd is engaged in the business of marketing, and distribution of finished pharmaceutical formulations
The company manufactures and distributors of a broad range of pharmaceutical formulations covering multiple therapeutic areas: antacids & PPIs, pain management, anti-inflammatories, antibiotics, cardiology & antidiabetics, neuropsychiatry, dental, injectable parenterals, syrups, nutraceuticals, sachets, and more.
Products:
Aptus Pharma: Focuses on acute therapies i.e, anti-infectives, pain management, etc.
Aptus CD care: Focused on chronic therapies
Aptus Wellcare: Offers wellness and nutraceutical products
Aptus Global: Export in overseas market
As of March 31, 2025, the company has 194 pharmaceutical formulations in more than eleven therapeutic segments.
Its warehouse is located over 15,732 sq. Feet and 1989 sq. feet in Ahmedabad, Gujarat. Its distribution model includes 125 direct and sub distributors and a sales team of 54 field personnel.
As of March 31, 2025, the company had 70 employees.
Competitive Strengths
Diversified product portfolio
Robust distribution network
Strategic manufacturing alliances across Gujarat, Uttarakhand and Himachal Pradesh
Competitive and cost-effective pricing
Experienced management team
Objectives of IPO
The Company Aptus Pharma IPO proposes to utilise the Net Proceeds from the Issue towards the following objects:
S.No.
Objects of the Issue
Expected Amount (₹ in crores)
1
Capital Expenditure for Office Premises with furniture and Industrial Racks
1.63
2
Working Capital
8.00
3
General corporate purposes
Disclaimer
All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions.
We are not a SEBI Registered analyst. Readers must consult a qualified financial advisor prior to making any actual investment decisions, based on Information published on this application.
No financial information whatsoever published anywhere, within this application, should be considered as advice to buy or sell securities or invest in IPOs, or as a guide to doing so in any way whatsoever
Please read all Tearms and conditions , and agree to use the App